Leerink Partnrs Predicts Stronger Earnings for Genmab A/S

Genmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for shares of Genmab A/S in a report issued on Thursday, May 8th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of $1.68 for the year, up from their prior forecast of $1.59. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S's Q4 2025 earnings at $0.62 EPS and FY2026 earnings at $1.98 EPS.

Several other equities analysts have also recently issued reports on the company. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Finally, Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.23 on Monday, hitting $19.08. 1,706,170 shares of the stock traded hands, compared to its average volume of 1,104,190. The company has a market capitalization of $12.23 billion, a PE ratio of 10.97, a P/E/G ratio of 2.65 and a beta of 1.04. The business has a 50 day simple moving average of $19.90 and a 200 day simple moving average of $20.82. Genmab A/S has a one year low of $17.24 and a one year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP bought a new stake in shares of Genmab A/S during the 4th quarter valued at $41,740,000. Renaissance Technologies LLC lifted its position in Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after purchasing an additional 139,722 shares in the last quarter. Brandywine Global Investment Management LLC lifted its position in Genmab A/S by 6.0% during the first quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock valued at $33,627,000 after purchasing an additional 97,633 shares in the last quarter. Two Sigma Investments LP grew its holdings in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after purchasing an additional 938,455 shares during the period. Finally, Two Sigma Advisers LP increased its position in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after buying an additional 1,038,400 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.